Capstone Investment Advisors
TEVA icon

Capstone Investment Advisors’s Teva Pharmaceuticals TEVA Stock Holding History

Capstone Investment Advisors’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-12,730
Closed -$133K – 2542
2023
Q4 		$133K Buy
+12,730
New +$119K ﹤0.01% 1892
2019
Q3 		– Sell
-52,800
Closed -$487K – 1449
2019
Q2 		$487K Buy
+52,800
New +$637K ﹤0.01% 1111
2017
Q2 		– Sell
-1,300
Closed -$40.2K – 920
2017
Q1 		$41K Buy
+1,300
New +$44.4K ﹤0.01% 827

Other funds holding TEVA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
IAM
Ion Asset Management Herzliya, Israel $911M AUM 24.97% 1-Year Est. Return
PF
Phoenix Financial Givatayim, Israel $10.5B AUM 49.21% 1-Year Est. Return
MIFH
Migdal Insurance & Financial Holdings Petach Tikva, Israel $11.5B AUM 52.5% 1-Year Est. Return
CI
Clal Insurance Tel-Aviv, Israel $16.6B AUM 68.34% 1-Year Est. Return
MMH
Menora Mivtachim Holdings Ramat Gan, Israel $21.1B AUM 40.03% 1-Year Est. Return
SPC
Slate Path Capital New York $6.73B AUM 95.97% 1-Year Est. Return
LIM
Lingotto Investment Management London, United Kingdom $5.06B AUM 91.14% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return

Capstone Investment Advisors's TEVA Position: Q1 2024 in Review

Capstone Investment Advisors sold out of Teva Pharmaceuticals (TEVA) in Q1 2024, closing a stake of 12,730 shares — an estimated $133K sold.

Capstone Investment Advisors first reported a position in TEVA in Q1 2017 and held it in 3 quarters. The position peaked at $487K in Q2 2019. 481 funds tracked by Wall St. Rank hold TEVA as of Q1 2024.

  • Capstone Investment Advisors reported no remaining Teva Pharmaceuticals position as of Q1 2024 after selling out during the quarter.
  • Capstone Investment Advisors sold 12,730 Teva Pharmaceuticals shares in Q1 2024, an estimated $133K.
  • Capstone Investment Advisors first reported a position in Teva Pharmaceuticals in Q1 2017 and held it in 3 quarters.
  • Capstone Investment Advisors's Teva Pharmaceuticals position peaked at $487K in Q2 2019.
  • 481 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q1 2024.

Based on Capstone Investment Advisors's 13F filing for Q1 2024, filed 1 May 2024.